The National Pharmaceutical Pricing Authority (NPPA) has introduced a new rule capping trade margins at 30% for 137 non-scheduled anti-cancer drug formulations. This rule, effective from November 9, 2026, is expected to reduce the maximum retail prices (MRPs) of these medicines by up to 70%, depending on their current price structures. The goal is to make cancer treatment more affordable by limiting excessive margins in the distribution chain.
- The NPPA’s measure covers 137 anti-cancer drug formulations, including immunotherapy drugs.
- Trade margins are capped at 30%, effective November 9, 2026.
- Price reductions could be as high as 70% for some medicines.
- Hospital chains and pharmaceutical companies with oncology exposure are likely to be affected.
- The impact on company revenues and profits depends on their exposure to the affected drugs.
What drugs are affected by the NPPA’s margin cap?
The list includes 137 formulations, many of which are immunotherapy drugs used to treat various types of cancer. Some notable medicines covered are denosumab, pegfilgrastim, bevacizumab, pembrolizumab, durvalumab, and osimertinib. These drugs are widely used in oncology treatments and represent a significant portion of cancer drug sales.
How will the margin cap affect drug prices?
The NPPA has capped trade margins at 30%, which means that distributors and sellers cannot charge more than this margin over the cost price. This is expected to lower the maximum retail prices by up to 70% for some medicines, depending on their existing price structures. The measure aims to reduce excessive profits in the supply chain and improve affordability for patients.
What is the impact on hospitals like Max Healthcare and Apollo Hospitals?
Hospitals that sell anti-cancer medicines through their pharmacies, such as Max Healthcare and Apollo Hospitals, may see changes in revenue from these sales. The overall impact will depend on how much of their oncology business involves the 137 affected formulations and their procurement costs. While lower drug prices might reduce margins, improved affordability could increase patient volumes over time. The net effect on revenue and profits remains uncertain.
How will pharmaceutical companies like Sun Pharma and Dr Reddy’s be affected?
Sun Pharmaceutical Industries and Dr Reddy’s Laboratories have oncology portfolios that include some of the affected drugs. The impact on these companies depends on which of their medicines are on the list and how the margin cap influences their sales and distribution. Since the 30% cap applies to trade margins rather than directly to manufacturers’ prices, it does not necessarily mean a proportional drop in their profits. Detailed product-level analysis is needed to understand the earnings impact.
What should investors consider regarding these changes?
Investors need to assess the exposure of Max Healthcare, Apollo Hospitals, Sun Pharma, and Dr Reddy’s to the specific formulations covered by the NPPA notification. While the stock prices of these companies may react to the announcement, the actual effect on their earnings will depend on how much their business relies on the affected drugs. Monitoring product-level sales and margins will be key to understanding the long-term impact.
Frequently Asked Questions
Q: When will the NPPA margin cap take effect?
A: The margin cap will be effective from November 9, 2026.
Q: Which drugs are included in the NPPA’s list?
A: The list includes 137 anti-cancer drug formulations, such as immunotherapy medicines and drugs like denosumab, pegfilgrastim, bevacizumab, pembrolizumab, durvalumab, and osimertinib.
Q: How much can drug prices decrease due to this measure?
A: Maximum retail prices of affected medicines could reduce by up to 70%, depending on their current price structures.
Q: Does the margin cap directly reduce pharmaceutical companies’ profits?
A: Not necessarily. The cap limits trade margins in the distribution chain but does not automatically translate into an equal reduction in manufacturers’ profits.
Q: How might hospitals be affected by this change?
A: Hospitals selling these medicines may see changes in revenue from drug sales, but increased affordability could lead to higher patient volumes, potentially offsetting some losses.
